Six patients were receiving TNF-α inhibitors only, and 10 patients (all with rheumatic disease) had additional treatment with methotrexate (5 patients), leflunomide (3 patients), methylprednisolone (1 patient) or meloxicam (1 patient). Here, TNF is linked to rheumatic disorder.